Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 6:45 PM
Ignite Modification Date:
2025-12-25 @ 4:16 PM
NCT ID:
NCT00618657
Group ID:
EG001
Title:
Arm II (HER-2 Negative)
Description:
Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
Carboplatin: Given IV
paclitaxel albumin-stabilized nanoparticle formulation: Given IV
bevacizumab: Given IV
magnetic resonance imaging: Optional correlative studies
therapeutic conventional surgery: Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
Deaths Number Affected:
11
Deaths Number At Risk:
None
Serious Number Affected:
1
Serious Number At Risk:
85
Other Number Affected:
50
Other Number At Risk:
85
Study:
NCT00618657
Results Section:
NCT00618657
Adverse Events Module:
NCT00618657